1975 Volume 23 Issue 6 Pages 2131-2137
With amikacin solution (100 mg/ml), a series of experimental and clinical studies were made in our clinic. The results obtained were as follows.
(1) The intramuscular administration of amikacin solution at a dose of 4.0 mg/kg yielded a peak serum concentration of 9.18 μg/ml at 1 hour, 3.11 μg/ml at 3 hours and 0.45 μg/ml at 6 hours, respectively. In comparison between this solution and an aqueous solution prepared from amikacin powder for injection by cross over method, both serum concentrations resembled eath other. The urinary excretion rate of the former within 6 hours was 59.2% of the given dose. This was similar to that of the latter, being 48.9%.
(2) Thirty hospitalized children with acute infections as mentioned below were treated mainly with amikacin. The overall clinical effectiveness was shown to be about 90%. The relation between diseases and daily doses in the clinical course was as follows.
Acute tonsillitis and acute lacunar tonsillitis ……4.0-5.0 mg/kg/day
Acute bronchitis ……5.0 mg/kg/day
Acute bronchopneumonia ……7.0-10.0 mg/kg/day
Acute colicystitis ……4.0 mg/kg/day
Whooping cough ……6.0-8.0 mg/kg/day
(3) In these children with bronchopneumonia, hemolytic infections or whooping cough, the liver and renal function tests (S-GOT, S-GPT and BUN) were made before intramuscular administration and 10 days after the onset of consecutive intramuscular administration. No abnormal elevations were observed in any of the function tests.
(4) The consecutive intramuscular administration of amikacin solution was done throughout 10 days. No local changes caused by the intramuscular administration, particularly such as induration, were observed in any of the cases.
